A
Aquestive Therapeutics, Inc. (AQST)
NGM – Real Time Price. Currency in USD
4.16
-0.18 (-4.15%)
At close: May 12, 2026, 4:00 PM EDT
4.25
+0.09 (2.13%)
After-hours: May 12, 2026, 7:21 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
4.16
-0.18 (-4.15%)
At close: May 12, 2026, 4:00 PM EDT
4.25
+0.09 (2.13%)
After-hours: May 12, 2026, 7:21 PM EDT
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company’s proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
| Name | Position |
|---|---|
| Dr. Matthew Greenhawt B.Sc., M.B.A., M.D. | Chief Medical Officer |
| Dr. Matthew William Davis M.D., R.Ph. | Chief Development Officer |
| Dr. Melina T. Cioffi Pharm.D. | Senior Vice President of Regulatory Affairs |
| Mr. A. Ernest Toth Jr. | Senior VP & CFO |
| Mr. Daniel Barber | CEO, President & Director |
| Mr. Peter E. Boyd | Senior Vice President of Information Technology & Chief People Officer |
| Mr. Thomas A. Zalewski | Chief Legal Officer & Chief Compliance Officer |
| Ms. Cassie Jung | Chief Operating Officer |
| Ms. Lori J. Braender BSBA, Esq., J.D. | Corporate Secretary |
| Ms. Sherry Korczynski | Chief Commercial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-04-24 | DEFA14A | ny20064249x2_defa14a.htm |
| 2026-04-24 | DEF 14A | ny20064249x1_def14a.htm |
| 2026-03-30 | 8-K | aqst-20260330.htm |
| 2026-03-20 | 8-K | aqst-20260316.htm |
| 2026-03-04 | 8-K | aqst-20260303.htm |
| 2026-02-26 | 8-K | aqst-20260226.htm |
| 2026-02-02 | 8-K | aqst-20260130.htm |
| 2026-01-21 | S-8 | o116265s8.htm |
| 2026-01-09 | 8-K | aqst-20260109.htm |
| 2025-11-06 | 8-K | aqst-20251106.htm |